Bradley Pharmaceuticals, Inc., recently announced the launch of its authorized generic version for ADOXA&reg 150 mg strength doxycycline monohydrate tablets. In accordance with a licensing and distribution agreement with Par Pharmaceutical Companies, Inc., Par began immediate shipments of the 150 mg strength tablets after the approval of another generic product. ADOXA&reg is an antibiotic therapy primarily used for the treatment of acne. “While this strength of ADOXA® represented approximately 18.5% of Bradley’s 2006 net sales, we proactively planned for this launch to commence once a generic version became available,” stated Daniel Glassman, President and CEO of Bradley Pharmaceuticals. “Since 2005, Par has been our exclusive partner with authorized generic ADOXA&reg formulations and maintains about a 55% market share of previous formulations of ADOXA&reg generics, including the 50 mg and 100 mg strengths of ADOXA&reg.”